Bederocin

Drug Profile

Bederocin

Alternative Names: methionyl tRNA synthetase inhibitor; REP 8839

Latest Information Update: 02 Mar 2009

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Cardiovascular Systems
  • Class Antibacterials; Quinolines; Small molecules; Thiophenes
  • Mechanism of Action Methionine tRNA ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Skin and soft tissue infections; Staphylococcal infections

Most Recent Events

  • 02 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics added to the Bacterial Infections antimicrobial activity section
  • 26 Jun 2007 Clinical data added to the adverse events section
  • 30 Oct 2006 Phase-I clinical trials in Staphylococcal infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top